Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05087628 · ClinicalTrials.gov registry record · Phase 2
PRV-3279-2a Trial in Systemic Lupus
A Phase 2 study, sponsored by Provention Bio, a Sanofi Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT05087628 is a Phase 2 study that was terminated before completion, run by Provention Bio, a Sanofi Company. The registered enrollment target is 28 participants.
The verdict
NCT05087628, a Phase 2 study, was terminated before completion, sponsored by Provention Bio, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid treatment.
Interventions
- OTHER Placebo
- BIOLOGICAL PRV-3279
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-01-20 |
| Est. Completion | 2024-06-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05087628
The ClinicalTrials.gov registry entry for NCT05087628 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Provention Bio, a Sanofi Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05087628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05087628 about?
NCT05087628 is a clinical study titled "PRV-3279-2a Trial in Systemic Lupus". The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid treatment.
What is the current status of trial NCT05087628?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2022-01-20. Estimated completion is 2024-06-24.
What interventions are being tested in trial NCT05087628?
The interventions under investigation include: Placebo (OTHER), PRV-3279 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05087628?
This trial is sponsored by Provention Bio, a Sanofi Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.